Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2163 August 2025

APPLICANT (stamp or sticker acceptable)		PATIENT NHI:	REFERRER Reg No:	
Reg No:		First Names:	First Names:	
lame:		Surname:	Surname:	
ddress:		DOB:	Address:	
		Address:		
			Fax Number:	
laparib				
and	Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation Patient has newly diagnosed, advanced disease and Patient has received one line** of previous treatment with platinum-based chemotherapy and Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen			
or	Patient has received at least two lines** of previous treatment with platinum-based chemotherapy and Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy and Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen and Patient has not previously received funded olaparib treatment			
and and and	Treatment to be administered as i	hin 12 weeks of the patient's last dose of the immedia maintenance treatment in combination with other chemotherapy	ately preceding platinum-based regimen	

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2163 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Renewal — Ovarian cancer Current approval Number (if known):				

I confirm the above details are correct and that in signing this form I understand I may be audited.

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.